ZOZO, Inc. (TYO:3092)

Sage Therapeutics Income Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	216,772	213,131	197,016	183,423	166,199	147,402
Revenue Growth (YoY)	7.56%	8.18%	7.41%	10.36%	12.75%	17.44%
Cost of Revenue	14,650	14,819	13,869	12,081	10,026	7,370
Gross Profit	202,122	198,312	183,147	171,342	156,173	140,032
Selling, General & Admin	131,594	128,814	119,224	112,410	104,135	93,463
Operating Expenses	136,336	133,556	123,016	114,752	106,541	95,922
Operating Income	65,786	64,756	60,131	56,590	49,632	44,110
Interest Expense	-165	-126	-77	-78	-74	-71
Interest & Investment Income	64	66	5	9	11	6
Currency Exchange Gain (Loss)	-244	-2	91	62	3	23
Other Non Operating Income (Expenses)	234	193	-387	132	81	317
EBT Excluding Unusual Items	65,633	64,887	59,763	56,715	49,653	44,385
Gain (Loss) on Sale of Investments	-138	-77	726	17	-	32
Gain (Loss) on Sale of Assets	-93	-101	-65	-64	-67	-554
Asset Writedown	-	-	-	-27	-81	-
Other Unusual Items	-	-	1	-	-220	-198
Pretax Income	65,402	64,709	60,425	56,641	49,285	43,665
Income Tax Expense	19,789	19,363	16,010	17,141	14,720	12,724
Earnings From Continuing Operations	45,613	45,346	44,415	39,500	34,565	30,941
Minority Interest in Earnings	-	-	-74	26	-73	-9
Net Income	45,613	45,346	44,341	39,526	34,492	30,932
Net Income to Common	45,613	45,346	44,341	39,526	34,492	30,932
Net Income Growth	3.09%	2.27%	12.18%	14.59%	11.51%	64.50%
Shares Outstanding (Basic)	890	891	898	900	900	916
Shares Outstanding (Diluted)	890	891	898	900	900	916
Shares Change (YoY)	-0.56%	-0.75%	-0.21%	-0.02%	-1.78%	0.02%
EPS (Basic)	51.22	50.90	49.40	43.94	38.34	33.77
EPS (Diluted)	51.22	50.90	49.40	43.94	38.34	33.77
EPS Growth	3.67%	3.04%	12.42%	14.62%	13.53%	64.47%
Free Cash Flow	-	55,315	34,592	27,714	38,673	41,566
Free Cash Flow Per Share	-	62.09	38.54	30.81	42.98	45.38
Dividend Per Share	35.667	35.667	34.667	21.667	19.333	13.667
Dividend Growth	2.89%	2.89%	60.00%	12.07%	41.46%	36.67%
Gross Margin	93.24%	93.05%	92.96%	93.41%	93.97%	95.00%
Operating Margin	30.35%	30.38%	30.52%	30.85%	29.86%	29.93%
Profit Margin	21.04%	21.28%	22.51%	21.55%	20.75%	20.98%
Free Cash Flow Margin	-	25.95%	17.56%	15.11%	23.27%	28.20%
EBITDA	70,753	69,498	63,974	59,100	52,013	46,536
EBITDA Margin	32.64%	32.61%	32.47%	32.22%	31.30%	31.57%
D&A For EBITDA	4,967	4,742	3,843	2,510	2,381	2,426
EBIT	65,786	64,756	60,131	56,590	49,632	44,110
EBIT Margin	30.35%	30.38%	30.52%	30.85%	29.86%	29.93%
Effective Tax Rate	30.26%	29.92%	26.50%	30.26%	29.87%	29.14%
Advertising Expenses	-	13,340	12,050	12,314	9,876	8,101

Source: S&P Global Market Intelligence. Standard template. Financial Sources.